In addition, CCL19-treated tumour-bearing mice showed significant reductions in TGF-β at the tumour sites; TGF-β is an immune inhibitory cytokine that may potently suppress Ag and presentation, antagonise CTL generation and macrophage activation (Bellone et al, 1999). The gene discussed is TGFB1; the disease is neoplasm.